David Ricks, Eli Lilly CEO (Paulo Nunes dos Santos/Bloomberg via Getty Images)

October 23, 2024 07:27 AM EDTUpdated 11:09 AM

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Kyle LaHucik

Biotech Correspondent

Eli Lilly’s Alzheimer’s drug Kisunla is likely to face an uphill uptake battle in the UK after its local cost-effectiveness watchdog NICE

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

A new dawn for psychedelics? Compass could be the first to find out

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

Weeks after TIGIT fail, iTeos decides to wind down

Strand Therapeutics reports promising start for mRNA cancer therapy

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation